Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells.
An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a study led by investigators at Weill Cornell Medicine. The finding suggests that the enzyme may be a potential target for f
According to new research, mice with colorectal cancer who have tumours with high levels of ammonia have fewer T cells and are less responsive to immunotherapy. Ammonia, which is crucial for anti-tumor immunity, has been demonstrated to impede the proliferation and operation of T cells.
The immune system, including T cells, is known to be compromised by severe viral infections and cancer, a condition known as immunological 'exhaustion'. The development of novel medicines for cancer or severe viral infections has a major focus on overcoming immunological fatigue.
Researchers at UConn Health, Yale, and Johns Hopkins have identified that some cancer cells can "cheat" by escaping constraints imposed by lack of oxygen, allowing the cancer cells to continue to grow.
The treatment, which is referred to as a "bispecific antibody," binds to both T cells and multiple myeloma cells and instructs the T cells, which are white blood cells that can be used to fight off diseases
A study supports the idea that some T cells that react to microbes also may react to normal human proteins, causing autoimmune disease. The findings promise to accelerate efforts to improve diagnostic tools and treatments for autoimmune diseases.
It is possible to determine how quickly the disease might advance by detecting immune cells in the cerebrospinal fluid after diagnosing ALS, according to researchers.
Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers. Now, investigators have reported highly promising early results for CAR T therapy in a small set of patients with the autoimmune disease lupus. Penn Medicine C